CA1098829A - Combination of drugs and a method for the selective control of the immune reactions evoked in a host by the administration of antigens - Google Patents
Combination of drugs and a method for the selective control of the immune reactions evoked in a host by the administration of antigensInfo
- Publication number
- CA1098829A CA1098829A CA292,030A CA292030A CA1098829A CA 1098829 A CA1098829 A CA 1098829A CA 292030 A CA292030 A CA 292030A CA 1098829 A CA1098829 A CA 1098829A
- Authority
- CA
- Canada
- Prior art keywords
- drugs
- cells
- mice
- combination
- host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 180
- 239000003814 drug Substances 0.000 title claims abstract description 180
- 239000000427 antigen Substances 0.000 title claims abstract description 80
- 102000036639 antigens Human genes 0.000 title claims abstract description 78
- 108091007433 antigens Proteins 0.000 title claims abstract description 78
- 230000008105 immune reaction Effects 0.000 title claims abstract description 13
- 230000000763 evoking effect Effects 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title abstract description 14
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims abstract description 72
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 55
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229960001999 phentolamine Drugs 0.000 claims abstract description 39
- 229960003878 haloperidol Drugs 0.000 claims abstract description 36
- 229960003638 dopamine Drugs 0.000 claims abstract description 28
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 28
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims abstract description 21
- 230000000903 blocking effect Effects 0.000 claims abstract description 17
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 16
- 230000001965 increasing effect Effects 0.000 claims abstract description 16
- 230000003291 dopaminomimetic effect Effects 0.000 claims abstract description 12
- 229940076279 serotonin Drugs 0.000 claims abstract description 12
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 12
- 150000003943 catecholamines Chemical class 0.000 claims abstract description 10
- 239000000890 drug combination Substances 0.000 claims abstract description 7
- 229960002888 oxitriptan Drugs 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 6
- 108010051696 Growth Hormone Proteins 0.000 claims description 4
- 239000000674 adrenergic antagonist Substances 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- 230000010412 perfusion Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 2
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 claims description 2
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 claims description 2
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 claims description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 claims description 2
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims description 2
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 claims description 2
- 229960000394 droperidol Drugs 0.000 claims description 2
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims description 2
- -1 flumisone Chemical compound 0.000 claims description 2
- 229940102213 injectable suspension Drugs 0.000 claims description 2
- 229960002589 iproclozide Drugs 0.000 claims description 2
- GGECDTUJZOXAAR-UHFFFAOYSA-N iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 claims description 2
- 229940070023 iproniazide Drugs 0.000 claims description 2
- 229960002672 isocarboxazid Drugs 0.000 claims description 2
- 229960004502 levodopa Drugs 0.000 claims description 2
- 229960000758 moperone Drugs 0.000 claims description 2
- AGAHNABIDCTLHW-UHFFFAOYSA-N moperone Chemical compound C1=CC(C)=CC=C1C1(O)CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 AGAHNABIDCTLHW-UHFFFAOYSA-N 0.000 claims description 2
- 229960003057 nialamide Drugs 0.000 claims description 2
- 229960001779 pargyline Drugs 0.000 claims description 2
- 229960003418 phenoxybenzamine Drugs 0.000 claims description 2
- 229960002776 pipamperone Drugs 0.000 claims description 2
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003741 tranylcypromine Drugs 0.000 claims description 2
- 229960002341 trifluperidol Drugs 0.000 claims description 2
- GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 claims description 2
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims 2
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims 2
- GCTIFOZRSFMVGO-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-4-fluoro-1-phenylbutan-1-one;ethanamine Chemical compound CCN.C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1C(F)CCC(=O)C1=CC=CC=C1 GCTIFOZRSFMVGO-UHFFFAOYSA-N 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 51
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 85
- 210000004027 cell Anatomy 0.000 description 63
- 229940088597 hormone Drugs 0.000 description 30
- 239000005556 hormone Substances 0.000 description 30
- 238000002347 injection Methods 0.000 description 30
- 239000007924 injection Substances 0.000 description 30
- 210000001185 bone marrow Anatomy 0.000 description 27
- 229940090044 injection Drugs 0.000 description 27
- 230000037396 body weight Effects 0.000 description 25
- 239000000306 component Substances 0.000 description 25
- 230000000735 allogeneic effect Effects 0.000 description 23
- 210000004989 spleen cell Anatomy 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 230000028993 immune response Effects 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 238000011081 inoculation Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 238000011740 C57BL/6 mouse Methods 0.000 description 12
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 229960000258 corticotropin Drugs 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 210000002798 bone marrow cell Anatomy 0.000 description 9
- 239000002054 inoculum Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 8
- 102000006771 Gonadotropins Human genes 0.000 description 8
- 108010086677 Gonadotropins Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000002622 gonadotropin Substances 0.000 description 8
- 229940094892 gonadotropins Drugs 0.000 description 8
- 208000024908 graft versus host disease Diseases 0.000 description 8
- 208000009329 Graft vs Host Disease Diseases 0.000 description 7
- 229960001140 cyproheptadine Drugs 0.000 description 7
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 6
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 6
- 230000016784 immunoglobulin production Effects 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241001494479 Pecora Species 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000010411 postconditioning Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229960001552 chlorprothixene Drugs 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000003176 neuroleptic agent Substances 0.000 description 4
- 230000002295 serotoninergic effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- 238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 3
- 206010058141 Skin graft rejection Diseases 0.000 description 3
- 102100038803 Somatotropin Human genes 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 239000000910 agglutinin Substances 0.000 description 3
- 239000002160 alpha blocker Substances 0.000 description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical group C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000001294 luteotrophic effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000003488 releasing hormone Substances 0.000 description 3
- 238000011640 AKR mouse Methods 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 206010013883 Dwarfism Diseases 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 101150058845 SYNRG gene Proteins 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- JBJSVEVEEGOEBZ-SCZZXKLOSA-N coenzyme B Chemical compound OP(=O)(O)O[C@H](C)[C@@H](C(O)=O)NC(=O)CCCCCCS JBJSVEVEEGOEBZ-SCZZXKLOSA-N 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000037321 sleepiness Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- HYUIDAKMNFQPTI-UHFFFAOYSA-N 4-(ethylamino)benzene-1,2-diol Chemical compound CCNC1=CC=C(O)C(O)=C1 HYUIDAKMNFQPTI-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001529297 Coregonus peled Species 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000004218 Orcein Substances 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940045024 blockade Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000043 immunodepressive effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000002122 leukaemogenic effect Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009955 peripheral mechanism Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB49826/76 | 1976-11-30 | ||
| GB49826/76A GB1600119A (en) | 1976-11-30 | 1976-11-30 | Combination of drugs for the selective control of the immune reactions evoked in a host by the administration of antigens |
| GB2681777 | 1977-06-27 | ||
| GB26.817/77 | 1977-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1098829A true CA1098829A (en) | 1981-04-07 |
Family
ID=26258445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA292,030A Expired CA1098829A (en) | 1976-11-30 | 1977-11-29 | Combination of drugs and a method for the selective control of the immune reactions evoked in a host by the administration of antigens |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4310535A (enExample) |
| JP (1) | JPS5396333A (enExample) |
| CA (1) | CA1098829A (enExample) |
| DE (1) | DE2753394A1 (enExample) |
| FR (1) | FR2373287A1 (enExample) |
| IL (1) | IL53452A (enExample) |
| IT (1) | IT1092158B (enExample) |
| NL (1) | NL7713244A (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447947A (en) * | 1990-02-26 | 1995-09-05 | Arc 1 | Compositions and methods of treatment of sympathetically maintained pain |
| US6559186B1 (en) | 1990-02-26 | 2003-05-06 | Arc 1, Inc. | Compositions and methods of treatment of sympathetically maintained pain |
| US5070084A (en) * | 1990-02-26 | 1991-12-03 | Campbell James N | Treatment of sympathetically maintained pain |
| US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
| US6432401B2 (en) * | 2000-05-12 | 2002-08-13 | Novalar Pharmaceuticals, Inc. | Local anesthetic methods and kits |
| US8026266B2 (en) * | 2005-11-08 | 2011-09-27 | Arcion Therapeutics, Inc. | Treatment of length dependent neuropathy |
| US9616123B1 (en) * | 2012-03-05 | 2017-04-11 | Robert L. Knobler | Method and compound for treatment of menopausal symptoms |
-
1977
- 1977-11-23 IL IL53452A patent/IL53452A/xx unknown
- 1977-11-29 JP JP14324277A patent/JPS5396333A/ja active Pending
- 1977-11-29 FR FR7735899A patent/FR2373287A1/fr active Granted
- 1977-11-29 US US05/855,546 patent/US4310535A/en not_active Expired - Lifetime
- 1977-11-29 CA CA292,030A patent/CA1098829A/en not_active Expired
- 1977-11-30 NL NL7713244A patent/NL7713244A/xx not_active Application Discontinuation
- 1977-11-30 DE DE19772753394 patent/DE2753394A1/de not_active Withdrawn
- 1977-11-30 IT IT52002/77A patent/IT1092158B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| NL7713244A (nl) | 1978-06-01 |
| FR2373287B1 (enExample) | 1980-08-22 |
| JPS5396333A (en) | 1978-08-23 |
| IT1092158B (it) | 1985-07-06 |
| US4310535A (en) | 1982-01-12 |
| IL53452A0 (en) | 1978-01-31 |
| FR2373287A1 (fr) | 1978-07-07 |
| DE2753394A1 (de) | 1978-06-01 |
| IL53452A (en) | 1980-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pollack et al. | Specific killing of tumor cells in vitro in the presence of normal lymphoid cells and sera from hosts immune to the tumor antigens | |
| Graves et al. | Antiprotozoan activity of nonspecific cytotoxic cells (NCC) from the channel catfish (Ictalurus punctatus). | |
| US7993660B2 (en) | Method of increasing immunological effect | |
| Pierpaoli et al. | Pharmacological control of the immune response by blockade of the early hormonal changes following antigen injection | |
| WO2001016180A2 (en) | Cd40 agonist compositions and methods of use | |
| HU197358B (en) | Process for producing human antitumour substance and pharmaceuticals comprising same | |
| CA1098829A (en) | Combination of drugs and a method for the selective control of the immune reactions evoked in a host by the administration of antigens | |
| US20130108579A1 (en) | Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases | |
| Pierpaoli et al. | Pharmacologic Control of the Hormonally Modulated Immune Response: III. Prolongation of Allogeneic Skin Graft Rejection and Prevention of Runt Disease by a Combination of Drugs Acting on Neuroendocrine Functions | |
| Waymack et al. | Blood transfusions as an immunomodulator—A review | |
| Hellmann et al. | Antilymphocytic serum and tumour dissemination | |
| Limpens et al. | Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative | |
| Paterson et al. | Transfer of allergic encephalomyelitis using splenectomized albino rats. | |
| GB1600119A (en) | Combination of drugs for the selective control of the immune reactions evoked in a host by the administration of antigens | |
| EP0705111A1 (de) | Mittel zur beeinflussung von hyperaktivierten immunologischen effektorzellen | |
| Matsuura et al. | Cyclophosphamide-induced tolerance in fully allogeneic heart transplantation in mice | |
| Lai Lin et al. | Dependence of immunity to IB leukemia on an adjuvant effect of immunizing cell preparations | |
| US4778824A (en) | Method for suppressing a transplantation immunity and treating an allergic disease and an autoimmune disease | |
| Cannon et al. | Reinvestigation of the biological activities of diacetylapomorphine and “Triacetylapomorphine” | |
| AU609120B2 (en) | Use of ODC inhibitors, dacarbazine, and interferon in the treatment of malignant melanoma | |
| Judd et al. | CARDIAC TRANSPLANTATION IN MICE: V. PROLONGATION OF ALLOGRAFTS WITH CELL-FREE EXTRACTS AND ANTITHYMOCYTE GLOBULIN | |
| Tsuru et al. | Cholera toxin-induced tolerance to allografts in mice | |
| Starzl | The mystique of transplantation: biologic and psychiatric considerations | |
| Levy et al. | The spleen in Friend leukemia. II. Nonleukemic nature of spleen stroma | |
| MAJOOR et al. | Requirement for both MHC and non-MHC antigens residing on the same erythrocyte for donor erythrocyte-mediated prolongation of rat renal allograft survival |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |